SYNG Pharmaceuticals Inc

Profile

SYNG has developed, EndoID a new first-in-class diagnostic test for Endometriosis. It is commercially available in India and seeking distributors for EndoID (consumer and CLIA) and strategic investors/partners for a diagnostic, accompanied by non-hormonal therapy. SYNG also has additional assets in AI-powered diagnostics for Sepsis, an AI-powered Therapy Platform for Cocaine Deaddiction and an AI-Powered Cognitive Platform for ADHD, Autism, Dementia and several Psychiatric Conditions.

syng pharmaceuticals inc

Website

syngpharma.com

Contact


Event details

Date: June 22 - 25, 2026

Event contact

Patricia Cosgrove
Senior International Market Consultant
U.S.A. & Europe

Participants

23 in total